Valrubicin 2433483 208005055 2008-04-25T00:49:10Z Chowbok 54304 clean up, Replaced: ® → using [[Project:AutoWikiBrowser|AWB]] {{drugbox | IUPAC_name = [2-oxo-2-[2,5,12-trihydroxy-4- [5-hydroxy-6-methyl-4- (2,2,2-trifluoroacetyl) amino-tetrahydropyran-2-yl] oxy-7-methoxy-6,11-dioxo-1,2,3,4-tetrahydrotetracen- 2-yl]-ethyl] pentanoate | image = Valrubicin.svg | CAS_number = 56124-62-0 | ATC_prefix = L01 | ATC_suffix = DB09 | ATC_supplemental = | PubChem = 41744 | DrugBank = APRD00662 | C=34 | H=36 | F=3 | N=1 | O=13 | molecular_weight = 723.644 g/mol | bioavailability = | protein_bound = >99% | metabolism = | elimination_half-life = | pregnancy_category = | legal_status = | routes_of_administration = }} '''Valrubicin''' (N-trifluoroacetyladriamycin-14-valerate, Valstar) is a [[chemotherapy]] [[medication|drug]] used to treat [[bladder cancer]]. Valrubicin is a semisynthetic analog of the [[anthracycline]] [[doxorubicin]], and is administered by infusion directly into the [[Urinary bladder|bladder]]. ==Dosage== 800 mg weekly for 6 weeks ==Side effects== *[[hematuria|Blood in urine]] *[[Urinary incontinence|Incontinence]] *[[dysuria|painful or difficult urination]] *Unusually frequent urination {{Chemotherapeutic agents}} [[Category:chemotherapeutic agents]] [[Category:cancer treatments]] [[Category:Quinones]] {{pharma-stub}}